Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Byrna Technologies Inc (BYRN) vs Pfizer Inc (PFE) Price & Performance

Byrna Technologies IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Byrna Technologies Inc vs Pfizer Inc — how do they compare? Byrna Technologies Inc trades at $4.32 (market cap $106.74M), while Pfizer Inc trades at $26.3 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 1421.5× Byrna Technologies Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Byrna Technologies Inc pays none. Which is the better fit depends on your goals.

BYRNPFE
Market Cap
$106.74M$151.73B
Sector
TechnologyHealth
52-Week High
$27.63$28.56
52-Week Low
$3.18$23.60
Enterprise Value
$98.35M$203.22B
Volume
29,869,932
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Byrna Technologies Inc

BYRN trades at $4.32, down 10.93% amid weak Q2 2026 results, with revenue declining 42.5% and a significant EPS miss. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with negative net income and ROE. Recent management changes and marketing initiatives aim to address sales challenges, while an ongoing legal investigation adds uncertainty.

The outlook is mixed; analyst consensus is 71% buy with potential from new leadership and product expansion, but execution risk is high given profit declines and competitive pressures. Investors should weigh turnaround efforts against persistent operational weaknesses and legal overhangs for near-term volatility.

Pfizer Inc

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Byrna Technologies Inc

Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.

Read more on BYRN

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE